NEW OREANS (EGMN) - Pomalidomide, a novel third-generation immunomodulatory agent in early trials, is drawing responses in patients with relapsed and refractory multiple myeloma that has progressed when treated with its predecessors, lenalidomide and thalidomide."Structurally, it is very similar to lenalidomide and thalidomide, but small differences in structure mean very important differences in terms of side effect profile, efficacy, and potency," Dr. Martha Q. Lacy of the Mayo Clinic in Rochester,...